Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a retrospective, observational, multicentre study to evaluate treatment patterns and outcomes of patients diagnosed with locally advanced or metastatic EGFRm NSCLC in Belgium
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with EGFR mutation positive NSCLC |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 1L treatment | Drug | chemotherapy, EGFR TKI, immunotherapy, other |
|
| Measure | Description | Time Frame |
|---|---|---|
| demographic characteristics of patients diagnosed between 1 September 2015 and 31 December 2017 | 28 months | |
| NSCLC characteristics at diagnosis between 1 september 2015 and 31 December 2017 | 28 months | |
| NSCLC disease characteristics at start of 2L or 3L treatment during observation window | observation window: between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. Descriptive statitistics will be used to analyse these endpoints. | 36 months |
| Type of treatment received during 1L, 2L or 3L treatment during the observation window | observation window: between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. Descriptive statitistics will be used to analyse these endpoints. | 36 months |
| Time on treatment during 1L, 2L or 3L treatment during the observation window | observation window: between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. Descriptive statitistics will be used to analyse these endpoints. | 36 months |
| Proportion of patients receiving a definitive, systemic therapy for NSCLC or no definitive, systemic therapy for NSCLC/best supportive care treatment after progression on their previous therapy | observation window: between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. Descriptive statitistics will be used to analyse these endpoints. |
| Measure | Description | Time Frame |
|---|---|---|
| PFS for 1L, 2L or 3L treatment during the observation window | observation window: between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. Kaplan-Meier analysis will be used. | 36 months |
| Time-to-treatment discontinuation for 1L, 2L and 3L treatment during the observation window |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients diagnosed with advanced or metastatic EGFRm NSCLC between 1 september 2015 and 31 December 2017
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Antwerp | 2020 | Belgium | |||
| Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33710523 | Derived | Cuppens K, Lodewyckx L, Demedts I, Decoster L, Colinet B, Deschepper K, Janssens A, Galdermans D, Pieters T; REVEAL Study Group. Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study. Drugs Real World Outcomes. 2021 Jun;8(2):141-152. doi: 10.1007/s40801-021-00243-w. Epub 2021 Mar 12. |
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
| 2L Treatment | Drug | Chemotherapy, EGFR TKI, immunotherapy, other |
|
| 3L treatment | Drug | chemotherapy, EGFR TKI, immunotherapy, other |
|
| 36 months |
| Reason for discontinuation after 1L, 2L or 3L treatment during observation window | observation window: between date of diagnosis until the data cut-off, 1 september 2018, end of clinical activity or death, whichever comes first. Descriptive statistics will be used to analyse these endpoints. | 36 months |
| EGFR testing characteristics at diagnosis between 1 september 2015 and 31 December 2017 | 28 months |
| EGFR testing characteristics after progression on previous treatment | observation window: between date of diagnosis until the data cut-off, 01 September 2018 until end of clinical activity or death, whichever comes first. Descriptive statistics will be used to analyse these endpoints. | 36 months |
observation window: between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. Kaplan-Meier analysis will be used. |
| 36 months |
| Time to start of subsequent treatment after 1L and 2L treatment during the observation window | observation window: between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. Kaplan-Meier analysis will be used. | 36 months |
| OS during observation window | OS will be measured overall for all EGFRm NSCLC patients and depending on receipt of Osimertinib treatment and line of Osimertinib treatment. observation window: between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. Kaplan-Meier analysis will be used. | 36 months |
| Bouge |
| 5004 |
| Belgium |
| Research Site | Brussels | 1090 | Belgium |
| Research Site | Brussels | 1200 | Belgium |
| Research Site | Charleroi | 6000 | Belgium |
| Research Site | Edegem | 2650 | Belgium |
| Research Site | Ghent | 9000 | Belgium |
| Research Site | Hasselt | 3500 | Belgium |
| Research Site | Mechelen | 2800 | Belgium |
| Research Site | Mons | 7000 | Belgium |
| Research Site | Roeselare | 8800 | Belgium |
| Research Site | Sint-Niklaas | 9100 | Belgium |
| Research Site | Sint-Truiden | 3800 | Belgium |
| Research Site | Turnhout | 2300 | Belgium |
| Research Site | Yvoir | 5530 | Belgium |
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| D009362 | Neoplasm Metastasis |
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D009385 | Neoplastic Processes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D013812 | Therapeutics |
Not provided
Not provided
Not provided